Metagenomi (MGX) Competitors $1.65 -0.04 (-2.37%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends MGX vs. FATE, BNTC, PYXS, ACB, TRVI, BMEA, TCRX, STRO, CYBN, and MOLNShould you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Fate Therapeutics (FATE), Benitec Biopharma (BNTC), Pyxis Oncology (PYXS), Aurora Cannabis (ACB), Trevi Therapeutics (TRVI), Biomea Fusion (BMEA), TScan Therapeutics (TCRX), Sutro Biopharma (STRO), Cybin (CYBN), and Molecular Partners (MOLN). These companies are all part of the "pharmaceutical products" industry. Metagenomi vs. Fate Therapeutics Benitec Biopharma Pyxis Oncology Aurora Cannabis Trevi Therapeutics Biomea Fusion TScan Therapeutics Sutro Biopharma Cybin Molecular Partners Metagenomi (NASDAQ:MGX) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, community ranking, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk. Do institutionals and insiders hold more shares of MGX or FATE? 97.5% of Fate Therapeutics shares are owned by institutional investors. 5.0% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts recommend MGX or FATE? Metagenomi presently has a consensus price target of $15.50, indicating a potential upside of 839.39%. Fate Therapeutics has a consensus price target of $6.75, indicating a potential upside of 204.05%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts plainly believe Metagenomi is more favorable than Fate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30 Which has preferable earnings & valuation, MGX or FATE? Metagenomi has higher earnings, but lower revenue than Fate Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetagenomi$44.76M1.38-$68.25MN/AN/AFate Therapeutics$63.53M3.98-$160.93M-$1.65-1.35 Does the MarketBeat Community favor MGX or FATE? Fate Therapeutics received 463 more outperform votes than Metagenomi when rated by MarketBeat users. However, 94.44% of users gave Metagenomi an outperform vote while only 68.09% of users gave Fate Therapeutics an outperform vote. CompanyUnderperformOutperformMetagenomiOutperform Votes1794.44% Underperform Votes15.56%Fate TherapeuticsOutperform Votes48068.09% Underperform Votes22531.91% Is MGX or FATE more profitable? Metagenomi has a net margin of -134.27% compared to Fate Therapeutics' net margin of -1,325.43%. Metagenomi's return on equity of -43.23% beat Fate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Metagenomi-134.27% -43.23% -18.86% Fate Therapeutics -1,325.43%-45.88%-33.95% Does the media refer more to MGX or FATE? In the previous week, Metagenomi and Metagenomi both had 21 articles in the media. Fate Therapeutics' average media sentiment score of 0.24 beat Metagenomi's score of 0.05 indicating that Fate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 1 Positive mention(s) 18 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fate Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryMetagenomi beats Fate Therapeutics on 8 of the 14 factors compared between the two stocks. Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get Metagenomi News Delivered to You Automatically Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGX vs. The Competition Export to ExcelMetricMetagenomiBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.25M$2.93B$5.01B$8.81BDividend YieldN/A1.89%5.16%4.06%P/E RatioN/A45.25134.3717.77Price / Sales1.38360.241,158.6875.18Price / CashN/A160.0933.5332.53Price / Book0.243.734.674.68Net Income-$68.25M-$41.63M$119.07M$226.08M7 Day Performance-12.23%-4.73%-1.83%-1.04%1 Month Performance-14.06%-6.53%-3.62%1.04%1 Year PerformanceN/A25.63%31.63%26.28% Metagenomi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGXMetagenomi2.8114 of 5 stars$1.65-2.4%$15.50+839.4%N/A$63.25M$44.76M0.00236Analyst ForecastFATEFate Therapeutics3.9121 of 5 stars$2.22+1.8%$6.75+204.1%-14.6%$252.84M$63.53M-1.35550Analyst UpgradeBNTCBenitec Biopharma2.2948 of 5 stars$10.66+7.9%$22.60+112.0%+202.8%$247.53M$80,000.000.0020Positive NewsPYXSPyxis Oncology1.0428 of 5 stars$3.82-8.2%$9.57+150.6%+165.3%$247.38MN/A0.0060News CoverageGap UpHigh Trading VolumeACBAurora Cannabis0.6391 of 5 stars$4.24+1.4%N/A-11.0%$232.52M$200.35M-5.581,073TRVITrevi Therapeutics3.4144 of 5 stars$2.77-7.7%$7.43+168.2%+113.1%$230.60MN/A0.0020BMEABiomea Fusion3.4346 of 5 stars$6.28-2.2%$30.50+385.7%-39.1%$227.58MN/A-1.5750TCRXTScan Therapeutics2.6162 of 5 stars$4.12-2.1%$12.00+191.3%-10.6%$223.02M$21.05M0.00100STROSutro Biopharma4.5351 of 5 stars$2.67-1.1%$12.14+354.8%-3.6%$222.64M$153.73M0.00240Analyst ForecastAnalyst RevisionCYBNCybin1.4673 of 5 stars$11.14+1.2%$138.00+1,139.3%N/A$222.59MN/A-1.6750Analyst ForecastGap UpMOLNMolecular Partners0.389 of 5 stars$5.20-4.8%$4.50-13.5%+19.8%$220.24M$7.84M0.00180 Related Companies and Tools Related Companies Fate Therapeutics Competitors Benitec Biopharma Competitors Pyxis Oncology Competitors Aurora Cannabis Competitors Trevi Therapeutics Competitors Biomea Fusion Competitors TScan Therapeutics Competitors Sutro Biopharma Competitors Cybin Competitors Molecular Partners Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MGX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MGX Stock Alerts